Quantcast

Industry news that matters to you.  Learn more

NIH to Fund Research on Alcohol-related Biomarkers

The National Institute on Alcohol Abuse and Alcoholism aims to fund small businesses and support the technology transfer of new biomarkers that can be used to detect alcohol-related organ damage and fetal exposure to alcohol, according to a new NIAAA grant notice.

NIH to Fund Research into Environmental Stress Biomarkers

The National Institute of Environmental Health Sciences will lead a program to give a total of $2.6 million for five or six projects over two years that seek to validate candidate biomarkers and technologies that measure biological responses to chemical toxicants and other environmental stressors.

Roche Obtains Co-Exclusive License to Develop PCR Assays Detecting Mutations in the PI3K Oncogene

Roche announced today that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays. Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to QIAGEN’s wholly owned subsidiary DxS, now QIAGEN Manchester. Financial details were not disclosed.

Biomarkers in Demand but CROs Cautious, Study

Demand for biomarker analysis is strong, but the pace of technological change is causing an investment headache for CROs according to a new report by Industry Standard Research (ISR). The research, “The State of Biomarkers in Drug Development,” examined the attitudes of 37 top pharmaceutical and biotechnology companies with regard to the use of biomarkers in clinical development.

TcLand Teams Up with Spanish Institute to Develop Assay for Predicting Response To TNFalpha Therapy

TcLand Expression is teaming up with the Hospital Vall d-Hebron Research Institute (HVIR) in Spain to develop a biomarker-based assay for predicting individual patients’ responses to TNFα blocker therapy for rheumatoid arthritis (RA). The collaboration agreement gives TcLand exclusive, worldwide rights to HVIR’s IP covering response-related biomarkers discovered by the Institute’s Sara Marsal, M.D., director of the Grup de Recerca de Reumatologia.